LIVE

DNTH

Dianthus Therapeutics, Inc.

DNTH

NASDAQ·Healthcare·Biotechnology·Mkt cap $3.8B

$92.40

▲ +2.43%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$17.88 - $98.70

P/E

-840.00

Fwd P/E

-25.45

Beta

0.07

Div Yield

0.00%

Avg Vol

889.1K

Shares Out

38.4M

Mkt Cap

$3.8B

Price action

Price chart

Up 390.8% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

3 reasons

  • Proprietary monoclonal antibody platform technology
  • Focus on underserved rare autoimmune and neurological diseases
  • Clinical-stage asset with potential for expedited regulatory pathways
▼

Bear Case

1 risk

  • Low volatility (beta 0.1).

Growth

Strong growth ahead

Phase 1 clinical trial advancement of DNTH103

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Stable

+4.9% over 3m

Quality

Excellent

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 11, 2026

“
LATEST RECAP

Earnings recap unavailable for this period.

EPS surprise · last 4Q

Q1 26

-$0.85

Q4 25

$2.59

Q3 25

-$0.97

Q2 25

-$0.88

Next: May 11, 2026

Revenue trend · last 8Q

—

—

+190%

+33%

-90%

-82%

-79%

-60%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$1.9M

$2.2M

$1.3M

$1.2M

$193.0K

$396.0K

$284.0K

$463.0K

Margins · last 8Q

Gross

—

Profit

-8819.4%

View full earnings history →

Wall Street consensus

9 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

9

100%

Hold

0%

Sell

0%

Median Price Target

$120.00

▲ +29.9% vs $92.40

Low $98.00
Median $120.00
High $125.00

Latest: Jefferies · Jun 10, 2026

3 analysts covering

View full analyst page →

vs Industry

How DNTH stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.